This document is a publication of a European patent application (EP2021115258A1) for an FGFR-targeted antagonistic short peptide, with Wenzhou Medical University as the applicant. The publication date is March 11, 2026. The application includes various IPC classifications related to peptides, genetic engineering, and pharmaceutical preparations for treating cancer.

As this is a patent publication, it does not impose direct compliance obligations on regulated entities. However, it is relevant for pharmaceutical and biotechnology companies involved in research and development of cancer therapeutics, particularly those targeting FGFR pathways. Companies should monitor the patent prosecution status and consider potential licensing or infringement implications if their activities overlap with the claimed subject matter.